Shots: Biogen’s decision of acquisition of TMS-007 based on the safety, imaging, and clinical outcome data from the P-IIa study which showed positive impacts on both blood vessel reopening in […]readmore
Tags : Acquisition
In an interview with PharmaShots, Gilles Cottier, Chief Executive Officer of Aceto shared his views on the acquisitions of A&C and IsleChem to highlight the company’s growth strategy. Shots: The […]readmore
Shots: StageBio and TPL Path Labs offers an expanded array of histopathology, molecular pathology, and related solutions to biopharma, medical device and academic researchers across the US, EU, and other […]readmore
Shots: Elanco has received the US FTC’s approval for its acquisition of Bayer Animal Health, representing the final antitrust clearance needed to complete the transaction, which continues track for closing […]readmore
Shots: South Korea’s FTC has approved Danaher’s $21.4 billion acquisition of GE biopharma on condition that the companies will sell eight bioprocessing product assets addressing monopoly concerns The FTC’s approval […]readmore
Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with […]readmore
Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for […]readmore
Shots: The acquisition is focus on development of vaccines for adenovirus types 4 and 7, and expanding the company’s vaccine product portfolio Emergent to pay an upfront ~$270M in cash […]readmore
Shots: Hologic to acquire Focal for its BioZorb marker, an implantable 3D marker helping surgeons to overcome challenges in breast conserving surgery, or lumpectomy used to mark tumor excision site […]readmore
Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by […]readmore